A study titled “Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.” by L.B. Holmes and a team from MassGeneral Hospital for Children (Boston, MA) published in the October, 2011 edition of Archives of Neurology further explores the link between in utero exposure to epilepsy drugs containing valproate (Depacon and other

Titled “Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.”, an article by K.J. Meador and a team from Emory University published in the April, 2009 edition of New England Journal of Medicine provides further insight into the adverse effects of prenatal exposure to antiepileptic drugs containing valproate, the

In February of this year, E. Campbell and a team from Royal Victoria Hospital (Belfast, UK) published a piece in Journal of Neurology, Neurosurgery, and Psychiatry titled “Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.” further demonstrating the link between exposure to

In March, 2013, a medical research team led by K.J. Meador published an article in Lancet Neurology titled “Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.”.  This team from Emory University (Atlanta) aimed to “We aimed to assess effects of commonly used antiepileptic drugs

In recent years, a number of independent medical research teams have determined that prenatal exposure to antiepileptic drugs branded Depacon, Depakene, and Depakote is linked to increased risk for birth defects.  Here, I will discuss research from one such team led by G. Veiby of The University of Bergen, Norway, specifically, an article titled “

In recent years, a number of studies have demonstrated that Depacon (sodium valproate) use during pregnancy is linked to increased risk for a range of serious birth defects.  This epilepsy drug by Abbott Laboratories, Inc. is often safe, but has been linked to autism, neurological birth defects, heart defects, craniofacial birth defects

In November 2011, Emily W.Y. Tung and Louise M. Winn of the Department of Pharmacology and Toxicology at Queen’s University in Ontario, Canada published a study titled “Valproic acid-induced DNA damage increases embryonic p27KIP1 and caspase-3 expression: A mechanism for valproic-acid induced neural tube defects” that studied the mechanism by which valproic acid causes neurological

In a 2013 study published in Reproductive Toxicology by Matteo Cassina et al. titled “Pregnancy outcome in women exposed to antiepileptic drugs: Teratogenic role of maternal epilepsy and its pharmacologic treatment” aimed to further evaluate the connection between valproic acid (the active ingredient in DepaconDepakene, and Depakote) and serious birth defects

In 1981, medical researcher F. Majewski, published a study in the Internaltional Journal of Biological Research in Pregnancy titled “The teratogenicity of Hydantoins and Barbiturates in Humans, With Considerations on the Etiology of Malformations and Cerebral Disturbances in the Children of Epileptic Parent”.

The study consisted of 194 children from epileptic mothers and